Editas Medicine
EDIT
199 hedge funds and large institutions have $912M invested in Editas Medicine in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 53 closing their positions.
80% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $11.7M
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.52% less ownership
Funds ownership: 89.21% → 83.69% (-5.5%)
13% less funds holding
Funds holding: 229 → 199 (-30)
33% less capital invested
Capital invested by funds: $1.35B → $912M (-$443M)
49% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$22.4M |
| 2 |
Renaissance Technologies
New York
|
+$5.52M |
| 3 |
Two Sigma Advisers
New York
|
+$4.78M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.33M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Valiant Capital Management
San Francisco,
California
|
-$11.2M |
| 2 |
D.E. Shaw & Co
New York
|
-$9.23M |
| 3 |
Morgan Stanley
New York
|
-$9.22M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.61M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$5.58M |
EDIT Hedge Fund Activity: Q1 2020 in Review
199 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2020, worth a combined $912M — down 33% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of EDIT and 27 opened new positions — a net loss of 26 holders — while 49 trimmed existing stakes and 69 added.
The largest buyer was ARK Investment Management, adding an estimated $22.4M. The largest seller was Valiant Capital Management, exiting entirely with an estimated $11.2M sold.
- 199 institutional investors held Editas Medicine (EDIT) as of Q1 2020, down from 229 in Q4 2019.
- Funds reported $912M of Editas Medicine stock for Q1 2020, down 33% quarter-over-quarter.
- 27 funds opened new Editas Medicine positions in Q1 2020 and 53 closed out, a net change of -26 holders.
- The largest Editas Medicine buyer in Q1 2020 was ARK Investment Management, an estimated $22.4M added.
- The largest Editas Medicine seller in Q1 2020 was Valiant Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2020.